1
|
Szapacs M, Jian W, Spellman D, Cunliffe J, Verburg E, Kaur S, Kellie J, Li W, Mehl J, Qian M, Qiu X, Sirtori FR, Rosenbaum AI, Sikorski T, Surapaneni S, Wang J, Wilson A, Zhang J, Xue Y, Post N, Huang Y, Goykhman D, Yuan L, Fang K, Casavant E, Chen L, Fu Y, Huang M, Ji A, Johnson J, Lassman M, Li J, Saad O, Sarvaiya H, Tao L, Wang Y, Zheng N, Dasgupta A, Abhari MR, Ishii-Watabe A, Saito Y, Mendes Fernandes DN, Bower J, Burns C, Carleton K, Cho SJ, Du X, Fjording M, Garofolo F, Kar S, Kavetska O, Kossary E, Lu Y, Mayer A, Palackal N, Salha D, Thomas E, Verhaeghe T, Vinter S, Wan K, Wang YM, Williams K, Woolf E, Yang L, Yang E, Bandukwala A, Hopper S, Maher K, Xu J, Brodsky E, Cludts I, Irwin C, Joseph J, Kirshner S, Manangeeswaran M, Maxfield K, Pedras-Vasconcelos J, Solstad T, Thacker S, Tounekti O, Verthelyi D, Wadhwa M, Wagner L, Yamamoto T, Zhang L, Zhou L. 2022 White Paper on Recent Issues in Bioanalysis: ICH M10 BMV Guideline & Global Harmonization; Hybrid Assays; Oligonucleotides & ADC; Non-Liquid & Rare Matrices; Regulatory Inputs ( Part 1A - Recommendations on Mass Spectrometry, Chromatography and Sample Preparation, Novel Technologies, Novel Modalities, and Novel Challenges, ICH M10 BMV Guideline & Global Harmonization Part 1B - Regulatory Agencies' Inputs on Regulated Bioanalysis/BMV, Biomarkers/CDx/BAV, Immunogenicity, Gene & Cell Therapy and Vaccine). Bioanalysis 2023; 15:955-1016. [PMID: 37650500 DOI: 10.4155/bio-2023-0167] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 09/01/2023] Open
Abstract
The 16th Workshop on Recent Issues in Bioanalysis (16th WRIB) took place in Atlanta, GA, USA on September 26-30, 2022. Over 1000 professionals representing pharma/biotech companies, CROs, and multiple regulatory agencies convened to actively discuss the most current topics of interest in bioanalysis. The 16th WRIB included 3 Main Workshops and 7 Specialized Workshops that together spanned 1 week in order to allow exhaustive and thorough coverage of all major issues in bioanalysis, biomarkers, immunogenicity, gene therapy, cell therapy and vaccines. Moreover, in-depth workshops on the ICH M10 BMV final guideline (focused on this guideline training, interpretation, adoption and transition); mass spectrometry innovation (focused on novel technologies, novel modalities, and novel challenges); and flow cytometry bioanalysis (rising of the 3rd most common/important technology in bioanalytical labs) were the special features of the 16th edition. As in previous years, WRIB continued to gather a wide diversity of international, industry opinion leaders and regulatory authority experts working on both small and large molecules as well as gene, cell therapies and vaccines to facilitate sharing and discussions focused on improving quality, increasing regulatory compliance, and achieving scientific excellence on bioanalytical issues. This 2022 White Paper encompasses recommendations emerging from the extensive discussions held during the workshop and is aimed to provide the bioanalytical community with key information and practical solutions on topics and issues addressed, in an effort to enable advances in scientific excellence, improved quality and better regulatory compliance. Due to its length, the 2022 edition of this comprehensive White Paper has been divided into three parts for editorial reasons. This publication (Part 1A) covers the recommendations on Mass Spectrometry and ICH M10. Part 1B covers the Regulatory Agencies' Inputs on Bioanalysis, Biomarkers, Immunogenicity, Gene & Cell Therapy and Vaccine. Part 2 (LBA, Biomarkers/CDx and Cytometry) and Part 3 (Gene Therapy, Cell therapy, Vaccines and Biotherapeutics Immunogenicity) are published in volume 15 of Bioanalysis, issues 15 and 14 (2023), respectively.
Collapse
Affiliation(s)
| | | | | | | | | | | | | | | | - John Mehl
- GlaxoSmithKline, Collegeville, PA, USA
| | | | | | | | | | | | | | | | | | | | - Yongjun Xue
- Bristol-Myers Squibb, Lawrenceville, NJ, USA
| | | | - Yue Huang
- AstraZeneca, South San Francisco, CA, USA
| | | | | | | | | | | | | | | | | | | | | | | | - Ola Saad
- Genentech, South San Francisco, CA, USA
| | | | | | | | - Naiyu Zheng
- Bristol-Myers Squibb, Lawrenceville, NJ, USA
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | - Yang Lu
- US FDA, Silver Spring, MD, USA
| | | | | | | | | | | | | | | | | | | | | | - Li Yang
- US FDA, Silver Spring, MD, USA
| | - Eric Yang
- GlaxoSmithKline, Collegeville, PA, USA
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
2
|
Pan L, Mora J, Walravens K, Wagner L, Hopper S, Loo L, Bettoun D, Bond S, Dessy F, Downing S, Garofolo F, Gupta S, Henderson N, Irwin C, Ishii-Watabe A, Kar S, Jawa V, Joseph J, Malvaux L, Marshall JC, McDevitt J, Mohapatra S, Seitzer J, Smith J, Solstad T, Sugimoto H, Tounekti O, Wu B, Wu Y, Xu Y, Xu J, Yamamoto T, Yang L, Torri A, Kirshner S, Maxfield K, Vasconcelos JP, Abhari MR, Verthelyi D, Brodsky E, Carrasco-Triguero M, Kamerud J, Andisik M, Baltrukonis D, Bivi N, Cludts I, Coble K, Gorovits B, Gunn GR, Gupta S, Millner AH, Joyce A, Kubiak RJ, Kumar S, Liao K, Manangeeswaran M, Partridge M, Pine S, Poetzl J, Rajadhyaksha M, Rasamoelisolo M, Richards S, Song Y, Swanson S, Thacker S, Wadhwa M, Wolf A, Zhang L, Zhou L. 2022 White Paper on Recent Issues in Bioanalysis: FDA Draft Guidance on Immunogenicity Information in Prescription Drug Labeling, LNP & Viral Vectors Therapeutics/Vaccines Immunogenicity, Prolongation Effect, ADA Affinity, Risk-based Approaches, NGS, qPCR, ddPCR Assays ( Part 3 - Recommendations on Gene Therapy, Cell Therapy, Vaccines Immunogenicity & Technologies; Immunogenicity & Risk Assessment of Biotherapeutics and Novel Modalities; NAb Assays Integrated Approach). Bioanalysis 2023; 15:773-814. [PMID: 37526071 DOI: 10.4155/bio-2023-0135] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 08/02/2023] Open
Abstract
The 2022 16th Workshop on Recent Issues in Bioanalysis (WRIB) took place in Atlanta, GA, USA on September 26-30, 2022. Over 1000 professionals representing pharma/biotech companies, CROs, and multiple regulatory agencies convened to actively discuss the most current topics of interest in bioanalysis. The 16th WRIB included 3 Main Workshops and 7 Specialized Workshops that together spanned 1 week in order to allow exhaustive and thorough coverage of all major issues in bioanalysis, biomarkers, immunogenicity, gene therapy, cell therapy and vaccines. Moreover, in-depth workshops on ICH M10 BMV final guideline (focused on this guideline training, interpretation, adoption and transition); mass spectrometry innovation (focused on novel technologies, novel modalities, and novel challenges); and flow cytometry bioanalysis (rising of the 3rd most common/important technology in bioanalytical labs) were the special features of the 16th edition. As in previous years, WRIB continued to gather a wide diversity of international, industry opinion leaders and regulatory authority experts working on both small and large molecules as well as gene, cell therapies and vaccines to facilitate sharing and discussions focused on improving quality, increasing regulatory compliance, and achieving scientific excellence on bioanalytical issues. This 2022 White Paper encompasses recommendations emerging from the extensive discussions held during the workshop and is aimed to provide the bioanalytical community with key information and practical solutions on topics and issues addressed, in an effort to enable advances in scientific excellence, improved quality and better regulatory compliance. Due to its length, the 2022 edition of this comprehensive White Paper has been divided into three parts for editorial reasons. This publication (Part 3) covers the recommendations on Gene Therapy, Cell therapy, Vaccines and Biotherapeutics Immunogenicity. Part 1 (Mass Spectrometry and ICH M10) and Part 2 (LBA, Biomarkers/CDx and Cytometry) are published in volume 15 of Bioanalysis, issues 16 and 15 (2023), respectively.
Collapse
Affiliation(s)
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | - Vibha Jawa
- Bristol Myers Squibb, Lawrenceville, NJ, USA
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | - Yuan Song
- Genentech, South San Francisco, CA, USA
| | | | | | | | | | | | | |
Collapse
|
3
|
Kang HN, Wadhwa M, Knezevic I, Ondari C, Simao M. WHO guidelines on biosimilars: Toward improved access to safe and effective products. Ann N Y Acad Sci 2023; 1521:96-103. [PMID: 36694455 DOI: 10.1111/nyas.14965] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/26/2023]
Abstract
The World Health Assembly resolution on access to biotherapeutics in 2014 urges WHO and Member States to facilitate access to biotherapeutics while ensuring their quality, safety, and efficacy. While efforts to date have contributed to increased availability and better access to biotherapeutics, including biosimilars, huge gaps still remain, with lack of product access identified as a problem in many countries. A thorough review of the WHO guidelines on biosimilars issued in 2009 in view of technical developments, accumulated and emerging scientific evidence as well as experience in biosimilar evaluation since the release of the guidelines provided an opportunity to introduce greater flexibility and to reduce regulatory requirements in biosimilar development where possible. Based on the identification, draft revisions of the WHO guidelines were prepared with input from extensive consultation with various stakeholders and the broader public. The move toward a greater emphasis on quality and functional in vitro assessment enables the reduction of cost and timelines of development and supports streamlined regulatory approval as a first critical step toward product availability. This article includes the key updates that have been incorporated in the revised guidelines but are not restricted to these alone and should be read in conjunction with the guidelines.
Collapse
Affiliation(s)
- Hye-Na Kang
- World Health Organization, Access to Medicines and Health Products, Geneva, Switzerland
| | - Meenu Wadhwa
- Medicines and Healthcare Products Regulatory Agency, South Mimms, Potters Bar, UK
| | - Ivana Knezevic
- World Health Organization, Access to Medicines and Health Products, Geneva, Switzerland
| | - Clive Ondari
- World Health Organization, Access to Medicines and Health Products, Geneva, Switzerland
| | - Mariangela Simao
- World Health Organization, Access to Medicines and Health Products, Geneva, Switzerland
| |
Collapse
|
4
|
Bakshi M, Kaur J, Wadhwa M. Utilization of tomato (Lycopersicon esculentum) pomace with or without waste bread in the ration of growing and adult male buffaloes. ANIM NUTR FEED TECHN 2023. [DOI: 10.5958/0974-181x.2023.00002.1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/26/2023]
|
5
|
Farley KA, Stack KM, Shuster DL, Horgan BHN, Hurowitz JA, Tarnas JD, Simon JI, Sun VZ, Scheller EL, Moore KR, McLennan SM, Vasconcelos PM, Wiens RC, Treiman AH, Mayhew LE, Beyssac O, Kizovski TV, Tosca NJ, Williford KH, Crumpler LS, Beegle LW, Bell JF, Ehlmann BL, Liu Y, Maki JN, Schmidt ME, Allwood AC, Amundsen HEF, Bhartia R, Bosak T, Brown AJ, Clark BC, Cousin A, Forni O, Gabriel TSJ, Goreva Y, Gupta S, Hamran SE, Herd CDK, Hickman-Lewis K, Johnson JR, Kah LC, Kelemen PB, Kinch KB, Mandon L, Mangold N, Quantin-Nataf C, Rice MS, Russell PS, Sharma S, Siljeström S, Steele A, Sullivan R, Wadhwa M, Weiss BP, Williams AJ, Wogsland BV, Willis PA, Acosta-Maeda TA, Beck P, Benzerara K, Bernard S, Burton AS, Cardarelli EL, Chide B, Clavé E, Cloutis EA, Cohen BA, Czaja AD, Debaille V, Dehouck E, Fairén AG, Flannery DT, Fleron SZ, Fouchet T, Frydenvang J, Garczynski BJ, Gibbons EF, Hausrath EM, Hayes AG, Henneke J, Jørgensen JL, Kelly EM, Lasue J, Le Mouélic S, Madariaga JM, Maurice S, Merusi M, Meslin PY, Milkovich SM, Million CC, Moeller RC, Núñez JI, Ollila AM, Paar G, Paige DA, Pedersen DAK, Pilleri P, Pilorget C, Pinet PC, Rice JW, Royer C, Sautter V, Schulte M, Sephton MA, Sharma SK, Sholes SF, Spanovich N, St Clair M, Tate CD, Uckert K, VanBommel SJ, Yanchilina AG, Zorzano MP. Aqueously altered igneous rocks sampled on the floor of Jezero crater, Mars. Science 2022; 377:eabo2196. [PMID: 36007009 DOI: 10.1126/science.abo2196] [Citation(s) in RCA: 11] [Impact Index Per Article: 5.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/08/2023]
Abstract
The Perseverance rover landed in Jezero crater, Mars, to investigate ancient lake and river deposits. We report observations of the crater floor, below the crater's sedimentary delta, finding the floor consists of igneous rocks altered by water. The lowest exposed unit, informally named Séítah, is a coarsely crystalline olivine-rich rock, which accumulated at the base of a magma body. Fe-Mg carbonates along grain boundaries indicate reactions with CO2-rich water, under water-poor conditions. Overlying Séítah is a unit informally named Máaz, which we interpret as lava flows or the chemical complement to Séítah in a layered igneous body. Voids in these rocks contain sulfates and perchlorates, likely introduced by later near-surface brine evaporation. Core samples of these rocks were stored aboard Perseverance for potential return to Earth.
Collapse
Affiliation(s)
- K A Farley
- Division of Geological and Planetary Sciences, California Institute of Technology, Pasadena, CA 91125, USA
| | - K M Stack
- Jet Propulsion Laboratory, California Institute of Technology, Pasadena, CA 91109, USA
| | - D L Shuster
- Department of Earth and Planetary Science, University of California, Berkeley, Berkeley, CA 94720, USA
| | - B H N Horgan
- Department of Earth, Atmospheric, and Planetary Sciences, Purdue University, West Lafayette, IN 47907, USA
| | - J A Hurowitz
- Department of Geosciences, Stony Brook University, Stony Brook, NY 11794, USA
| | - J D Tarnas
- Jet Propulsion Laboratory, California Institute of Technology, Pasadena, CA 91109, USA
| | - J I Simon
- Center for Isotope Cosmochemistry and Geochronology, Astromaterials Research and Exploration Science Division, NASA Johnson Space Center, Houston, TX 77058, USA
| | - V Z Sun
- Jet Propulsion Laboratory, California Institute of Technology, Pasadena, CA 91109, USA
| | - E L Scheller
- Division of Geological and Planetary Sciences, California Institute of Technology, Pasadena, CA 91125, USA
| | - K R Moore
- Division of Geological and Planetary Sciences, California Institute of Technology, Pasadena, CA 91125, USA
| | - S M McLennan
- Department of Geosciences, Stony Brook University, Stony Brook, NY 11794, USA
| | - P M Vasconcelos
- School of Earth and Environmental Sciences, University of Queensland, Brisbane, QLD 4072, Australia
| | - R C Wiens
- Planetary Exploration Team, Los Alamos National Laboratory, Los Alamos, NM 87545, USA
| | - A H Treiman
- Lunar and Planetary Institute, Universities Space Research Association, Houston, TX 77058, USA
| | - L E Mayhew
- Department of Geological Sciences, University of Colorado, Boulder, Boulder, CO 80309, USA
| | - O Beyssac
- Institut de Minéralogie, de Physique des Matériaux et de Cosmochimie, Centre National de la Recherche Scientifique, Sorbonne Université, Muséum National d'Histoire Naturelle, 75005 Paris, France
| | - T V Kizovski
- Department of Earth Sciences, Brock University, St. Catharines, ON L2S 3A1, Canada
| | - N J Tosca
- Department of Earth Sciences, University of Cambridge, Cambridge CB2 3EQ, UK
| | - K H Williford
- Blue Marble Space Institute of Science, Seattle, WA 98104, USA
| | - L S Crumpler
- New Mexico Museum of Natural History and Science, Albuquerque, NM 8710, USA
| | - L W Beegle
- Jet Propulsion Laboratory, California Institute of Technology, Pasadena, CA 91109, USA
| | - J F Bell
- School of Earth and Space Exploration, Arizona State University, Tempe, AZ 85287, USA
| | - B L Ehlmann
- Division of Geological and Planetary Sciences, California Institute of Technology, Pasadena, CA 91125, USA
| | - Y Liu
- Jet Propulsion Laboratory, California Institute of Technology, Pasadena, CA 91109, USA
| | - J N Maki
- Jet Propulsion Laboratory, California Institute of Technology, Pasadena, CA 91109, USA
| | - M E Schmidt
- Department of Earth Sciences, Brock University, St. Catharines, ON L2S 3A1, Canada
| | - A C Allwood
- Jet Propulsion Laboratory, California Institute of Technology, Pasadena, CA 91109, USA
| | - H E F Amundsen
- Center for Space Sensors and Systems, University of Oslo, 2007 Kjeller, Norway
| | - R Bhartia
- Photon Systems Inc., Covina, CA 91725, USA
| | - T Bosak
- Department of Earth, Atmospheric and Planetary Sciences, Massachusetts Institute of Technology, Cambridge, MA 02139, USA
| | - A J Brown
- Plancius Research, Severna Park, MD 21146, USA
| | - B C Clark
- Space Science Institute, Boulder, CO 80301, USA
| | - A Cousin
- Institut de Recherche en Astrophysique et Planétologie, Université de Toulouse 3 Paul Sabatier, Centre National de la Recherche Scientifique, Centre National d'Etude Spatiale, 31400 Toulouse, France
| | - O Forni
- Institut de Recherche en Astrophysique et Planétologie, Université de Toulouse 3 Paul Sabatier, Centre National de la Recherche Scientifique, Centre National d'Etude Spatiale, 31400 Toulouse, France
| | - T S J Gabriel
- Astrogeology Science Center, US Geological Survey, Flagstaff, AZ 86001, USA
| | - Y Goreva
- Jet Propulsion Laboratory, California Institute of Technology, Pasadena, CA 91109, USA
| | - S Gupta
- Department of Earth Sciences and Engineering, Imperial College London, London SW7 2AZ, UK
| | - S-E Hamran
- Center for Space Sensors and Systems, University of Oslo, 2007 Kjeller, Norway
| | - C D K Herd
- Department of Earth and Atmospheric Sciences, University of Alberta, Edmonton, AB T6G 2E3, Canada
| | - K Hickman-Lewis
- Department of Earth Sciences, The Natural History Museum, London SW7 5BD, UK.,Dipartimento di Scienze Biologiche, Geologiche e Ambientali, Università di Bologna, 40126 Bologna, Italy
| | - J R Johnson
- Johns Hopkins University Applied Physics Laboratory, Laurel, MD 20723, USA
| | - L C Kah
- Department of Earth and Planetary Sciences, University of Tennessee, Knoxville, TN 37996, USA
| | - P B Kelemen
- Department of Earth and Environmental Sciences, Lamont Doherty Earth Observatory of Columbia University, Palisades, NY 10964, USA
| | - K B Kinch
- Niels Bohr Institute, University of Copenhagen, 1350 Copenhagen, Denmark
| | - L Mandon
- Laboratoire d'Etudes Spatiales et d'Instrumentation en Astrophysique, Observatoire de Paris, Centre National de la Recherche Scientifique, Sorbonne Université, Université Paris Diderot, 92195 Meudon, France
| | - N Mangold
- Laboratoire de Planétologie et Géosciences, Centre National de la Recherche Scientifique, Nantes Université, Université Angers, 44000 Nantes, France
| | - C Quantin-Nataf
- Laboratoire de Géologie de Lyon: Terre, Université de Lyon, Université Claude Bernard Lyon1, Ecole Normale Supérieure de Lyon, Université Jean Monnet Saint Etienne, Centre National de la Recherche Scientifique, 69622 Villeurbanne, France
| | - M S Rice
- Department of Geology, Western Washington University, Bellingham, WA 98225 USA
| | - P S Russell
- Department of Earth, Planetary, and Space Sciences, University of California, Los Angeles, Los Angeles, CA 90095, USA
| | - S Sharma
- Jet Propulsion Laboratory, California Institute of Technology, Pasadena, CA 91109, USA
| | - S Siljeström
- Department of Methodology, Textiles and Medical Technology, Research Institutes of Sweden, 11486 Stockholm, Sweden
| | - A Steele
- Earth and Planetary Laboratory, Carnegie Science, Washington, DC 20015, USA
| | - R Sullivan
- Cornell Center for Astrophysics and Planetary Science, Cornell University, Ithaca, NY 14853, USA
| | - M Wadhwa
- School of Earth and Space Exploration, Arizona State University, Tempe, AZ 85287, USA
| | - B P Weiss
- Jet Propulsion Laboratory, California Institute of Technology, Pasadena, CA 91109, USA.,Department of Earth, Atmospheric and Planetary Sciences, Massachusetts Institute of Technology, Cambridge, MA 02139, USA
| | - A J Williams
- Department of Geological Sciences, University of Florida, Gainesville, FL 32611, USA
| | - B V Wogsland
- Department of Earth and Planetary Sciences, University of Tennessee, Knoxville, TN 37996, USA
| | - P A Willis
- Jet Propulsion Laboratory, California Institute of Technology, Pasadena, CA 91109, USA
| | - T A Acosta-Maeda
- Hawai'i Institute of Geophysics and Planetology, University of Hawai'i at Mānoa, Honolulu, HI 96822, USA
| | - P Beck
- Institut de Planétologie et Astrophysique de Grenoble, Centre National de la Recherche Scientifique, Université Grenoble Alpes, 38000 Grenoble, France
| | - K Benzerara
- Institut de Minéralogie, de Physique des Matériaux et de Cosmochimie, Centre National de la Recherche Scientifique, Sorbonne Université, Muséum National d'Histoire Naturelle, 75005 Paris, France
| | - S Bernard
- Institut de Minéralogie, de Physique des Matériaux et de Cosmochimie, Centre National de la Recherche Scientifique, Sorbonne Université, Muséum National d'Histoire Naturelle, 75005 Paris, France
| | - A S Burton
- NASA Johnson Space Center, Houston, TX 77058, USA
| | - E L Cardarelli
- Jet Propulsion Laboratory, California Institute of Technology, Pasadena, CA 91109, USA
| | - B Chide
- Planetary Exploration Team, Los Alamos National Laboratory, Los Alamos, NM 87545, USA
| | - E Clavé
- Centre Lasers Intenses et Applications, Centre National de la Recherche Scientifique, Commissariat à l'Energie Atomique, Université de Bordeaux, 33400 Bordeaux, France
| | - E A Cloutis
- Centre for Terrestrial and Planetary Exploration, University of Winnipeg, Winnipeg, MB R3B 2E9, Canada
| | - B A Cohen
- NASA Goddard Space Flight Center, Greenbelt, MD 20771, USA
| | - A D Czaja
- Department of Geology, University of Cincinnati, Cincinnati, OH 45221, USA
| | - V Debaille
- Laboratoire G-Time, Université Libre de Bruxelles, 1050 Brussels, Belgium
| | - E Dehouck
- Laboratoire de Géologie de Lyon: Terre, Université de Lyon, Université Claude Bernard Lyon1, Ecole Normale Supérieure de Lyon, Université Jean Monnet Saint Etienne, Centre National de la Recherche Scientifique, 69622 Villeurbanne, France
| | - A G Fairén
- Centro de Astrobiología, Consejo Superior de Investigaciones Científicas-Instituto Nacional de Técnica Aeroespacial, 28850 Madrid, Spain.,Department of Astronomy, Cornell University, Ithaca, NY 14853, USA
| | - D T Flannery
- School of Earth and Atmospheric Sciences, Queensland University of Technology, Brisbane, QLD 4001, Australia
| | - S Z Fleron
- Department of Geosciences and Natural Resource Management, University of Copenhagen, 1350 Copenhagen, Denmark
| | - T Fouchet
- Laboratoire d'Etudes Spatiales et d'Instrumentation en Astrophysique, Observatoire de Paris, Centre National de la Recherche Scientifique, Sorbonne Université, Université Paris Diderot, 92195 Meudon, France
| | - J Frydenvang
- Globe Institute, University of Copenhagen, 1350 Copenhagen, Denmark
| | - B J Garczynski
- Department of Earth, Atmospheric, and Planetary Sciences, Purdue University, West Lafayette, IN 47907, USA
| | - E F Gibbons
- Department of Earth and Planetary Sciences, McGill University, Montreal, QC H3A 0E8, Canada
| | - E M Hausrath
- Department of Geoscience, University of Nevada, Las Vegas, Las Vegas, NV 89154, USA
| | - A G Hayes
- Department of Astronomy, Cornell University, Ithaca, NY 14853, USA
| | - J Henneke
- National Space Institute, Technical University of Denmark, 2800 Kongens Lyngby, Denmark
| | - J L Jørgensen
- National Space Institute, Technical University of Denmark, 2800 Kongens Lyngby, Denmark
| | - E M Kelly
- Hawai'i Institute of Geophysics and Planetology, University of Hawai'i at Mānoa, Honolulu, HI 96822, USA
| | - J Lasue
- Institut de Recherche en Astrophysique et Planétologie, Université de Toulouse 3 Paul Sabatier, Centre National de la Recherche Scientifique, Centre National d'Etude Spatiale, 31400 Toulouse, France
| | - S Le Mouélic
- Laboratoire de Planétologie et Géosciences, Centre National de la Recherche Scientifique, Nantes Université, Université Angers, 44000 Nantes, France
| | - J M Madariaga
- Department of Analytical Chemistry, University of the Basque Country, 48940 Leioa, Spain
| | - S Maurice
- Institut de Recherche en Astrophysique et Planétologie, Université de Toulouse 3 Paul Sabatier, Centre National de la Recherche Scientifique, Centre National d'Etude Spatiale, 31400 Toulouse, France
| | - M Merusi
- Niels Bohr Institute, University of Copenhagen, 1350 Copenhagen, Denmark
| | - P-Y Meslin
- Institut de Recherche en Astrophysique et Planétologie, Université de Toulouse 3 Paul Sabatier, Centre National de la Recherche Scientifique, Centre National d'Etude Spatiale, 31400 Toulouse, France
| | - S M Milkovich
- Jet Propulsion Laboratory, California Institute of Technology, Pasadena, CA 91109, USA
| | | | - R C Moeller
- Jet Propulsion Laboratory, California Institute of Technology, Pasadena, CA 91109, USA
| | - J I Núñez
- Johns Hopkins University Applied Physics Laboratory, Laurel, MD 20723, USA
| | - A M Ollila
- Los Alamos National Laboratory, Los Alamos, NM 87545 USA
| | - G Paar
- Institute for Information and Communication Technologies, Joanneum Research, 8010 Graz, Austria
| | - D A Paige
- Department of Earth, Planetary, and Space Sciences, University of California, Los Angeles, Los Angeles, CA 90095, USA
| | - D A K Pedersen
- National Space Institute, Technical University of Denmark, 2800 Kongens Lyngby, Denmark
| | - P Pilleri
- Institut de Recherche en Astrophysique et Planétologie, Université de Toulouse 3 Paul Sabatier, Centre National de la Recherche Scientifique, Centre National d'Etude Spatiale, 31400 Toulouse, France
| | - C Pilorget
- Institut d'Astrophysique Spatiale, Université Paris-Saclay, 91405 Orsay, France.,Institut Universitaire de France, Paris, France
| | - P C Pinet
- Institut de Recherche en Astrophysique et Planétologie, Université de Toulouse 3 Paul Sabatier, Centre National de la Recherche Scientifique, Centre National d'Etude Spatiale, 31400 Toulouse, France
| | - J W Rice
- School of Earth and Space Exploration, Arizona State University, Tempe, AZ 85287, USA
| | - C Royer
- Institut de Minéralogie, de Physique des Matériaux et de Cosmochimie, Centre National de la Recherche Scientifique, Sorbonne Université, Muséum National d'Histoire Naturelle, 75005 Paris, France
| | - V Sautter
- Institut de Minéralogie, de Physique des Matériaux et de Cosmochimie, Centre National de la Recherche Scientifique, Sorbonne Université, Muséum National d'Histoire Naturelle, 75005 Paris, France
| | - M Schulte
- Mars Exploration Program, Planetary Science Division, NASA Headquarters, Washington, DC 20546, USA
| | - M A Sephton
- Department of Earth Sciences and Engineering, Imperial College London, London SW7 2AZ, UK
| | - S K Sharma
- Hawai'i Institute of Geophysics and Planetology, University of Hawai'i at Mānoa, Honolulu, HI 96822, USA
| | - S F Sholes
- Jet Propulsion Laboratory, California Institute of Technology, Pasadena, CA 91109, USA
| | - N Spanovich
- Jet Propulsion Laboratory, California Institute of Technology, Pasadena, CA 91109, USA
| | - M St Clair
- Million Concepts, Louisville, KY 40204, USA
| | - C D Tate
- Department of Astronomy, Cornell University, Ithaca, NY 14853, USA
| | - K Uckert
- Jet Propulsion Laboratory, California Institute of Technology, Pasadena, CA 91109, USA
| | - S J VanBommel
- McDonnell Center for the Space Sciences and Department of Earth and Planetary Sciences, Washington University in St. Louis, St. Louis, MO 63130, USA
| | | | - M-P Zorzano
- Department of Astronomy, Cornell University, Ithaca, NY 14853, USA
| |
Collapse
|
6
|
Matejtschuk P, Bird C, Ezeajughi E, MacLellan-Gibson K, Wadhwa M. Impact of Formulation Choices on the Freeze-Drying of an Interleukin-6 Reference Material. Front Mol Biosci 2022; 9:868460. [PMID: 35860358 PMCID: PMC9289548 DOI: 10.3389/fmolb.2022.868460] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/02/2022] [Accepted: 05/11/2022] [Indexed: 11/20/2022] Open
Abstract
Formulation is critical to successful delivery of lyophilized biologics. We have compared the impact of buffer choice and the addition of sodium chloride (a formulant often viewed as unfavorable for freeze-drying applications) on the outcome of trial lyophilization of an interleukin-6 reference material. While phosphate buffer was a preferred choice and yielded well-formed cakes associated with fair recovery of biological activity, the resultant residual moisture content was high (2–4% w/w). By inclusion of isotonic levels of NaCl, the freeze-dried appearance and process were not impaired, but the residual moisture delivered was considerably reduced to levels <1% w/w. We postulate that this is due to the presence of a more open-cake structure and support this with evidence from thermal analysis and scanning electron microscopy. This work illustrates the importance of wide ranging empirical investigation of formulation options in order to optimize freeze-drying outcomes for biologics.
Collapse
Affiliation(s)
- Paul Matejtschuk
- Analytical and Biological Sciences, NIBSC, Medicines and Healthcare Products Regulatory Agency, Potters Bar, United Kingdom
- *Correspondence: Paul Matejtschuk,
| | - Christopher Bird
- Biotherapeutics, NIBSC, Medicines and Healthcare products Regulatory Agency, Potters Bar, United Kingdom
| | - Ernest Ezeajughi
- Analytical and Biological Sciences, NIBSC, Medicines and Healthcare Products Regulatory Agency, Potters Bar, United Kingdom
| | - Kirsty MacLellan-Gibson
- Analytical and Biological Sciences, NIBSC, Medicines and Healthcare Products Regulatory Agency, Potters Bar, United Kingdom
| | - Meenu Wadhwa
- Biotherapeutics, NIBSC, Medicines and Healthcare products Regulatory Agency, Potters Bar, United Kingdom
| |
Collapse
|
7
|
Wadhwa M, Kang HN, Thorpe R, Knezevic I, Aprea P, Bielsky MC, Ekman N, Heim HK, Joung J, Kurki P, Lacana E, Njue C, Nkansah E, Savkina M, Thorpe R, Yamaguchi T, Wadhwa M, Wang J, Weise M, Wolff-Holz E, Allam M, Bahaa H, Sayed M, Al-Oballi A, Alshahrani A, Baek D, Kim J, Chua H, Gangakhedkar J, Jagtap MP, Lyaskovsky T, Okudaira S, Ondee W, Sotomayor P, Ricra JS, Uviase J, Ahmed F, Rajendran Y, Defendi HT, Cho SO, Qu A, Acha V, Gencoglu M, Ho K, Baldrighi M, Schiestl M, Watson K, Spitzer E, Chong S, Fukushima A, Kang HN, Knezevic I, Pante G, Simao M. WHO informal consultation on revision of guidelines on evaluation of similar biotherapeutic products, virtual meeting, 30 June – 2 July 2021. Biologicals 2022; 76:1-9. [PMID: 35466023 PMCID: PMC9109723 DOI: 10.1016/j.biologicals.2022.03.001] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/07/2022] [Revised: 02/28/2022] [Accepted: 03/29/2022] [Indexed: 11/26/2022] Open
Abstract
The WHO informal consultation was held to promote the revision of WHO guidelines on evaluation of similar biotherapeutic products (SBPs) adopted by the Expert Committee on Biological Standardization (ECBS) in 2009. It was agreed in the past consultations that the evaluation principles in the guidelines are still valid, but a review was recommended to provide more clarity and case-by-case flexibility. The opportunity was therefore taken to review the experience and identify areas where the current guidance could be more permissive without compromising its basic principles, and where additional explanation could be provided regarding the possibility of reducing the amount of data needed for regulatory approval. The meeting participants applauded the leading role taken by the WHO in providing a much-needed streamlined approach for development and evaluation of SBPs which will provide efficient and cost-effective product development and increase patient access to treatments. It was recognized that the principles as currently described in the draft WHO guidelines are based on sound science and experience gained over the last fifteen years of biosimilar approvals. However, since these guidelines when finalised will constitute the global standard for biosimilar evaluation and assist national regulatory authorities in establishing revised guidance and regulatory practice in this complex area, it was felt that further revision and clarity on certain perspectives in specific areas was necessary to dispel uncertainties arising in the current revised version. This report describes the principles in the draft guidelines, including topics discussed and consensus reached. WHO guidelines serve as a basis for the development of national regulatory framework for biosimilars. Revision of guidelines is to provide more flexibility and clarification on data required for regulatory approval. Revised guidelines would contribute to improving consistency on regulatory decision and patient access to treatments.
Collapse
|
8
|
Kaur H, Wadhwa M, Hundal J, Bakshi M, Sharma A, Malhotra P, Bansal B. Effect of dietary supplementation of Acacia arabica bark dry extract on the enteric methane emission and performance of lactating buffaloes. ANIM NUTR FEED TECHN 2022. [DOI: 10.5958/0974-181x.2022.00001.4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/17/2022]
|
9
|
Wood VE, Groves K, Wong LM, Kong L, Bird C, Wadhwa M, Quaglia M, Matejtschuk P, Dalby PA. Protein Engineering and HDX Identify Structural Regions of G-CSF Critical to Its Stability and Aggregation. Mol Pharm 2021; 19:616-629. [PMID: 34965730 DOI: 10.1021/acs.molpharmaceut.1c00754] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/27/2022]
Abstract
The protein engineering and formulation of therapeutic proteins for prolonged shelf-life remain a major challenge in the biopharmaceutical industry. Understanding the influence of mutations and formulations on the protein structure and dynamics could lead to more predictive approaches to their improvement. Previous intrinsic fluorescence analysis of the chemically denatured granulocyte colony-stimulating factor (G-CSF) suggested that loop AB could subtly reorganize to form an aggregation-prone intermediate state. Hydrogen deuterium exchange mass spectrometry (HDX-MS) has also revealed that excipient binding increased the thermal unfolding transition midpoint (Tm) by stabilizing loop AB. Here, we have combined protein engineering with biophysical analyses and HDX-MS to reveal that increased exchange in a core region of the G-CSF comprising loop AB (ABI, a small helix, ABII) and loop CD packed onto helix B and the beginning of loop BC leads to a decrease in Tm and higher aggregation rates. Furthermore, some mutations can increase the population of the aggregation-prone conformation within the native ensemble, as measured by the greater local exchange within this core region.
Collapse
Affiliation(s)
- Victoria E Wood
- Department of Biochemical Engineering, University College London, Gower Street, London WC1E 6BT, U.K
| | - Kate Groves
- National Measurement Laboratory at LGC Ltd, Queens Road, Teddington TW11 0LY, U.K
| | - Lok Man Wong
- Department of Biochemical Engineering, University College London, Gower Street, London WC1E 6BT, U.K
| | - Luyan Kong
- Department of Biochemical Engineering, University College London, Gower Street, London WC1E 6BT, U.K
| | - Christopher Bird
- National Institute for Biological Standards and Control (NIBSC), Blanche Lane, South Mimms, Potters Bar, Hertfordshire EN6 3QG, U.K
| | - Meenu Wadhwa
- National Institute for Biological Standards and Control (NIBSC), Blanche Lane, South Mimms, Potters Bar, Hertfordshire EN6 3QG, U.K
| | - Milena Quaglia
- National Measurement Laboratory at LGC Ltd, Queens Road, Teddington TW11 0LY, U.K
| | - Paul Matejtschuk
- National Institute for Biological Standards and Control (NIBSC), Blanche Lane, South Mimms, Potters Bar, Hertfordshire EN6 3QG, U.K
| | - Paul A Dalby
- Department of Biochemical Engineering, University College London, Gower Street, London WC1E 6BT, U.K
| |
Collapse
|
10
|
Jia H, Harikumar P, Atkinson E, Rigsby P, Wadhwa M. The First WHO International Standard for Harmonizing the Biological Activity of Bevacizumab. Biomolecules 2021; 11:biom11111610. [PMID: 34827607 PMCID: PMC8615914 DOI: 10.3390/biom11111610] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/08/2021] [Revised: 10/15/2021] [Accepted: 10/25/2021] [Indexed: 11/22/2022] Open
Abstract
Several Bevacizumab products are approved for clinical use, with many others in late-stage clinical development worldwide. To aid the harmonization of potency assessment across different Bevacizumab products, the first World Health Organization (WHO) International Standard (IS) for Bevacizumab has been developed. Two preparations of a Bevacizumab candidate and comparator were assessed for their ability to neutralize and bind vascular endothelial growth factor (VEGF) using different bioassays and binding assays in an international collaborative study. Relative potency estimates were similar across different assays for the comparator or the duplicate-coded candidate sample. Variability in relative potency estimates was reduced when the candidate standard was used for calculation compared with various in-house reference standards, enabling harmonization in bioactivity evaluations. The results demonstrated that the candidate standard is suitable to serve as an IS for Bevacizumab, with assigned unitages for VEGF neutralization and VEGF binding activity. This standard coded 18/210 was established by the WHO Expert Committee on Biological Standardization, which is intended to support the calibration of secondary standards for product development and lifecycle management. The availability of IS 18/210 will help facilitate the global harmonization of potency evaluation to ensure patient access to Bevacizumab products with consistent safety, quality and efficacy.
Collapse
Affiliation(s)
- Haiyan Jia
- Division of Biotherapeutics, National Institute for Biological Standards and Control, Hertfordshire EN6 3QG, UK; (P.H.); (M.W.)
- Correspondence: ; Tel.: +44-1707-641413
| | - Parvathy Harikumar
- Division of Biotherapeutics, National Institute for Biological Standards and Control, Hertfordshire EN6 3QG, UK; (P.H.); (M.W.)
| | - Eleanor Atkinson
- Division of Technology Development and Infrastructure, National Institute for Biological Standards and Control, Hertfordshire EN6 3QG, UK; (E.A.); (P.R.)
| | - Peter Rigsby
- Division of Technology Development and Infrastructure, National Institute for Biological Standards and Control, Hertfordshire EN6 3QG, UK; (E.A.); (P.R.)
| | - Meenu Wadhwa
- Division of Biotherapeutics, National Institute for Biological Standards and Control, Hertfordshire EN6 3QG, UK; (P.H.); (M.W.)
| |
Collapse
|
11
|
Khatana S, Swarup N, Wadhwa M, Rehani S. SCROFULA: ANALYZING THE ASPIRATE TO AID IN EARLY DIAGNOSIS. Oral Surg Oral Med Oral Pathol Oral Radiol 2021. [DOI: 10.1016/j.oooo.2021.03.167] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
|
12
|
Patel S, Wadhwa M. Therapeutic use of specific tumour necrosis factor inhibitors in inflammatory diseases including COVID-19. Biomed Pharmacother 2021; 140:111785. [PMID: 34126316 PMCID: PMC8162906 DOI: 10.1016/j.biopha.2021.111785] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/30/2021] [Revised: 05/21/2021] [Accepted: 05/25/2021] [Indexed: 02/07/2023] Open
Abstract
Coronavirus disease 2019 (COVID-19) has caused significant devastation globally. Despite the development of several vaccines, with uncertainty around global uptake and vaccine efficacy, the need for effective therapeutic agents remains. Increased levels of cytokines including tumour necrosis factor are significant in the pathogenesis of COVID-19 and associated with poor outcomes including ventilator requirement and mortality. Repurposing tumour necrosis factor blocker therapy used in conditions such as rheumatoid arthritis and inflammatory bowel disease seems promising, with early feasibility data showing a reduction in circulation of pro-inflammatory cytokines and encouraging the evaluation of such interventions in preventing disease progression and clinical deterioration in patients with COVID-19. Here, we examine the biological activities of tumour necrosis factor inhibitors indicative of their potential in COVID-19 and briefly outline the randomised control trials assessing their benefit-risk profile in COVID-19 therapy.
Collapse
Affiliation(s)
- Serena Patel
- Downing College, Regent Street, Cambridge CB2 1DQ, UK; Ipswich Hospital, Heath Road, Ipswich IP4 5PD, UK
| | - Meenu Wadhwa
- NIBSC, MHRA, Blanche Lane, South Mimms, Hertfordshire EN6 3QG, UK.
| |
Collapse
|
13
|
Wadhwa M, Bird C, Atkinson E, Cludts I, Rigsby P. The First WHO International Standard for Adalimumab: Dual Role in Bioactivity and Therapeutic Drug Monitoring. Front Immunol 2021; 12:636420. [PMID: 33936049 PMCID: PMC8082443 DOI: 10.3389/fimmu.2021.636420] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/01/2020] [Accepted: 03/19/2021] [Indexed: 12/17/2022] Open
Abstract
The expanded availability of adalimumab products continues to widen patient access and reduce costs with substantial benefit to healthcare systems. However, the long-term success of these medicines is highly dependent on maintaining consistency in quality, safety and efficacy while minimizing any risk of divergence during life-cycle management. In recognition of this need and demand from global manufacturers, the World Health Organization (WHO) Expert Committee on Biological standardization established the WHO 1st International standard (IS) for Adalimumab (coded 17/236) in October 2019 with a defined unitage ascribed to each of the individual bioactivities evaluated in the study namely, TNF-α binding, TNF-α neutralization, complement dependent cytotoxicity and antibody-dependent cellular cytotoxicity. For development of the IS, two candidate standards were manufactured as per WHO recommendations. Analysis of extensive datasets generated by testing of a common set of samples including the candidate standards by multiple stakeholders including regulatory agencies using their own qualified assays in a large international collaborative study showed comparable biological activity for the tested candidates for the different activities. Use of a common standard significantly decreased the variability of bioassays and improved agreement in potency estimates. Data from this study clearly supports the utility of the IS as an important tool for assuring analytical assay performance, for bioassay calibration and validation, for identifying and controlling changes in bioactivity during life-cycle management and for global harmonization of adalimumab products. In addition, in a separate multi-center study which included involvement of hospital and clinical diagnostic laboratories, the suitability of the adalimumab IS for therapeutic drug monitoring assays was examined by analysis of data from testing of a common blind coded panel of adalimumab spiked serum samples representative of the clinical scenario along with the IS and in-house standards in diverse immunoassays/platforms. Both commercially available and in-house assays that are routinely used for assessing adalimumab trough levels were included. Excellent agreement in estimates for adalimumab content in the spiked samples was observed regardless of the standard or the method with inter-laboratory variability also similar regardless of the standard employed. This data, for the first time, provides support for the extended applicability of the IS in assays in use for therapeutic drug monitoring based on the mass content of the IS. The adalimumab IS, in fulfilling clinical demand, can help toward standardizing and harmonizing clinical monitoring assays for informed clinical decisions and/or personalized treatment strategies for better patient outcomes. Collectively, a significant role for the adalimumab IS in assuring the quality, safety and efficacy of adalimumab products globally is envisaged.
Collapse
Affiliation(s)
- Meenu Wadhwa
- Biotherapeutics Division, National Institute for Biological Standards and Control, Medicines and Healthcare Products Regulatory Agency, Potters Bar, United Kingdom
| | - Chris Bird
- Biotherapeutics Division, National Institute for Biological Standards and Control, Medicines and Healthcare Products Regulatory Agency, Potters Bar, United Kingdom
| | - Eleanor Atkinson
- Analytical and Biological Sciences Division, National Institute for Biological Standards and Control, Medicines and Healthcare Products Regulatory Agency, Potters Bar, United Kingdom
| | - Isabelle Cludts
- Biotherapeutics Division, National Institute for Biological Standards and Control, Medicines and Healthcare Products Regulatory Agency, Potters Bar, United Kingdom
| | - Peter Rigsby
- Analytical and Biological Sciences Division, National Institute for Biological Standards and Control, Medicines and Healthcare Products Regulatory Agency, Potters Bar, United Kingdom
| |
Collapse
|
14
|
Affiliation(s)
- Sandra Prior
- National Institute for Biological Standards and Control (NIBSC), South Mimms, United Kingdom.
| | - Clive Metcalfe
- National Institute for Biological Standards and Control (NIBSC), South Mimms, United Kingdom
| | - Simon E Hufton
- National Institute for Biological Standards and Control (NIBSC), South Mimms, United Kingdom
| | - Meenu Wadhwa
- National Institute for Biological Standards and Control (NIBSC), South Mimms, United Kingdom
| | - Christian K Schneider
- National Institute for Biological Standards and Control (NIBSC), South Mimms, United Kingdom.,Twincore Centre, Hannover Medical School, Hannover, Germany
| | - Chris Burns
- National Institute for Biological Standards and Control (NIBSC), South Mimms, United Kingdom
| |
Collapse
|
15
|
Kang HN, Thorpe R, Knezevic I, Baek D, Chirachanakul P, Chua HM, Dalili D, Foo F, Gao K, Habahbeh S, Hamel H, Nkansah E, Savkina M, Semeniuk O, Srivastava S, Neto JT, Wadhwa M, Yamaguchi T. Biosimilars – status in July 2020 in 16 countries. GaBI J 2021. [DOI: 10.5639/gabij.2021.1001.002] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Abstract
The World Health Organization has provided specific guidance for biosimilar products to assist regulators, manufacturers and other professionals involved in the development and evaluation of these products. The development and approval of biosimilars are important for health care, as they allow the marketing of safe, efficacious and affordable biological products. Since the first biosimilars were approved in the EU in 2006, a series of biosimilars have been approved in many countries/geographical regions. This manuscript provides the figures on the status of approved biosimilars in 16 countries based on the information from regulatory experts and from publicly available data. It is clear that increasing numbers of biosimilars are now available in many countries and provide more options for treatments. It is expected that adoption of biosimilars will allow affordable health care and greater patient access to important medicinal products. It will also contribute to the overall WHO goal recognized by the World Health Assembly in 2014 by adopting a resolution on access to biotherapeutic products including biosimilars and on ensuring their quality, safety and efficacy.
Collapse
|
16
|
Veena N, Hundal JS, Wadhwa M, Puniya AK. Factors affecting the milk yield, milk composition and physico-chemical parameters of ghee in lactating crossbred cows. IJDS 2021. [DOI: 10.33785/ijds.2021.v74i01.009] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/23/2022]
|
17
|
Bakshi M, Wadhwa M. Paddy Straw Pelletization with other Feedstuffs and its In Vitro Evaluation as Livestock Feed. ANIM NUTR FEED TECHN 2021. [DOI: 10.5958/0974-181x.2021.00050.0] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
18
|
Wadhwa M, Hundal J, Bakshi M. Ensiling and Utilization of Kinnow mandarin (Citrus reticulata) Waste and Empty Pea (Pisum sativum) Pods as Feed for Buffalo Calves. ANIM NUTR FEED TECHN 2021. [DOI: 10.5958/0974-181x.2021.00040.8] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
19
|
|
20
|
Wadhwa M, Saini J, Bakshi M. Utilization of bottle gourd (Lagenaria siceraria) pomace in the ration of goats. ANIM NUTR FEED TECHN 2021. [DOI: 10.5958/0974-181x.2021.00026.3] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
|
21
|
Kang HN, Thorpe R, Knezevic I, Casas Levano M, Chilufya MB, Chirachanakul P, Chua HM, Dalili D, Foo F, Gao K, Habahbeh S, Hamel H, Kim GH, Perez Rodriguez V, Putri DE, Rodgers J, Savkina M, Semeniuk O, Srivastava S, Tavares Neto J, Wadhwa M, Yamaguchi T. Regulatory challenges with biosimilars: an update from 20 countries. Ann N Y Acad Sci 2020; 1491:42-59. [PMID: 33222245 PMCID: PMC8247359 DOI: 10.1111/nyas.14522] [Citation(s) in RCA: 12] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/20/2020] [Revised: 09/29/2020] [Accepted: 10/13/2020] [Indexed: 11/29/2022]
Abstract
The World Health Organization (WHO) issued guidelines for the regulatory evaluation of biosimilars in 2009 and has provided considerable effort toward helping member states implement the evaluation principles in the guidelines into their regulatory practices. Despite this effort, a recent WHO survey (conducted in 2019–2020) has revealed four main remaining challenges: unavailable/insufficient reference products in the country; lack of resources; problems with the quality of some biosimilars (and even more with noninnovator products); and difficulties with the practice of interchangeability and naming of biosimilars. The following have been identified as opportunities/solutions for regulatory authorities to deal with the existing challenges: (1) exchange of information on products with other regulatory authorities and accepting foreign licensed and sourced reference products, hence avoiding conducting unnecessary (duplicate) bridging studies; (2) use of a “reliance” concept and/or joint review for the assessment and approval of biosimilars; (3) review and reassessment of the products already approved before the establishment of a regulatory framework for biosimilar approval; and (4) setting appropriate regulatory oversight for good pharmacovigilance, which is essential for the identification of problems with products and establishing the safety and efficacy of interchangeability of biosimilars.
Collapse
Affiliation(s)
- Hye-Na Kang
- Department of Health Product Policy and Standards, World Health Organization, Geneva, Switzerland
| | | | - Ivana Knezevic
- Department of Health Product Policy and Standards, World Health Organization, Geneva, Switzerland
| | - Mary Casas Levano
- General Directorate of Medicines Supplies and Drugs (DIGEMID), San Miguel, Peru
| | | | | | - Hui Ming Chua
- National Pharmaceutical Regulatory Agency, Selangor, Malaysia
| | - Dina Dalili
- Iran Food and Drug Administration, Tehran, Iran
| | | | - Kai Gao
- Shanghai University, Shanghai, People's Republic of China
| | | | | | - Gi Hyun Kim
- Ministry of Food and Drug Safety, Osong-eup, Republic of Korea
| | - Violeta Perez Rodriguez
- Centro para el Control Estatal de Medicamentos, Equipos y Dispositivos Médicos (CECMED), La Habana, Cuba
| | - Desi Eka Putri
- The Indonesian Food and Drug Authority, Jakarta, Indonesia
| | | | - Maria Savkina
- The Federal State Budgetary Institution "Scientific Centre for Expert Evaluation of Medicinal Products" of the Ministry of Health, Moscow, Russian Federation
| | | | - Shraddha Srivastava
- Central Drug Standards Control Organization (CDSCO), Ministry of Health & Family Welfare, New Delhi, India
| | | | - Meenu Wadhwa
- National Institute for Biological Standards and Control, Medicines and Healthcare products Regulatory Agency, Potters Bar, United Kingdom
| | | |
Collapse
|
22
|
Jurewicz AJG, Rieck KD, Hervig R, Burnett DS, Wadhwa M, Olinger CT, Wiens RC, Laming JM, Guan Y, Huss GR, Reisenfeld DB, Williams P. Magnesium isotopes of the bulk solar wind from Genesis diamond-like carbon films. Meteorit Planet Sci 2020; 55:352-375. [PMID: 32214784 PMCID: PMC7079557 DOI: 10.1111/maps.13439] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Grants] [Track Full Text] [Figures] [Subscribe] [Scholar Register] [Received: 12/09/2018] [Accepted: 12/10/2019] [Indexed: 06/10/2023]
Abstract
NASA's Genesis Mission returned solar wind (SW) to the Earth for analysis to derive the composition of the solar photosphere from solar material. SW analyses control the precision of the derived solar compositions, but their ultimate accuracy is limited by the theoretical or empirical models of fractionation due to SW formation. Mg isotopes are "ground truth" for these models since, except for CAIs, planetary materials have a uniform Mg isotopic composition (within ≤1‰) so any significant isotopic fractionation of SW Mg is primarily that of SW formation and subsequent acceleration through the corona. This study analyzed Mg isotopes in a bulk SW diamond-like carbon (DLC) film on silicon collector returned by the Genesis Mission. A novel data reduction technique was required to account for variable ion yield and instrumental mass fractionation (IMF) in the DLC. The resulting SW Mg fractionation relative to the DSM-3 laboratory standard was (-14.4‰, -30.2‰) ± (4.1‰, 5.5‰), where the uncertainty is 2ơ SE of the data combined with a 2.5‰ (total) error in the IMF determination. Two of the SW fractionation models considered generally agreed with our data. Their possible ramifications are discussed for O isotopes based on the CAI nebular composition of McKeegan et al. (2011).
Collapse
Affiliation(s)
- A. J. G. Jurewicz
- Center for Meteorite StudiesArizona State Universitym/c 6004TempeArizona85287USA
| | - K. D. Rieck
- New Mexico Consortium4200 West Jemez Road Suite 200Los AlamosNew Mexico87544USA
| | - R. Hervig
- School of Earth and Space ExplorationArizona State UniversityTempeArizona85287USA
| | - D. S. Burnett
- Department of Geology and Planetary SciencesCalifornia Institute of Technologym/c 100‐23PasadenaCalifornia91125USA
| | - M. Wadhwa
- School of Earth and Space ExplorationArizona State UniversityTempeArizona85287USA
| | - C. T. Olinger
- GET‐NSA, LLC, AU‐6219901 Germantown RdGermantownMaryland20875USA
| | - R. C. Wiens
- Los Alamos National Laboratory (Remote Sensing)ISR‐2, m/s C‐331Los AlamosNew Mexico87545USA
| | - J. M. Laming
- Naval Research LaboratorySpace Science DivisionCode 7684WashingtonDistrict of Columbia20375USA
| | - Y. Guan
- Geological and Planetary SciencesCalifornia Institute of Technologym/c 100‐10PasadenaCalifornia91125USA
| | - G. R. Huss
- Hawaii Institute of Geophysics and PlanetologyUniversity of Hawaii at Manoa1680 East‐West Road, Post 504HonoluluHawaii96822USA
| | - D. B. Reisenfeld
- Los Alamos National Laboratory ISR‐1Los AlamosNew Mexico87545USA
| | - P. Williams
- School of Molecular SciencesArizona State UniversityTempeArizona85287USA
| |
Collapse
|
23
|
Wadhwa M, Kang HN, Jivapaisarnpong T, Andalucia LR, Blades CDRZ, Casas Levano M, Chang W, Chew JY, Chilufya MB, Chirachanakul P, Cho HG, Cho YO, Choi KM, Chong S, Chua HM, Farahani AV, Gencoglu M, Ghobrial MRW, Guha P, Gutierrez Lugo MT, Ha SB, Habahbeh S, Hamel H, Hong Y, Iarutkin A, Jang H, Jayachandran R, Jivapaisarnpong T, Kang HN, Kim DY, Kim GH, Kim Y, Kwon HS, Larsen J, Lee AH, Lee J, Medvedeva K, Munkombwe Z, Oh I, Park J, Park J, Putri DE, Rodgers J, Ryu S, Savkina M, Schreitmueller T, Semeniuk O, Seo M, Shin YI, Shin J, Srivastava S, Song H, Song S, Tavares Neto J, Wadhwa M, Yamaguchi T, Youn HJD, Yun M. WHO implementation workshop on guidelines on procedures and data requirements for changes to approved biotherapeutic products, Seoul, Republic of Korea, 25-26 June 2019. Biologicals 2020; 65:50-59. [PMID: 31959504 DOI: 10.1016/j.biologicals.2019.12.008] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/19/2019] [Accepted: 12/20/2019] [Indexed: 10/25/2022] Open
Abstract
The first global workshop on implementation of the WHO guidelines on procedures and data requirements for changes to approved biotherapeutic products adopted by the WHO Expert Committee in 2018 was held in June 2019. The workshop participants recognized that the principles based on sound science and the potential for risk, as described in the WHO Guidelines on post-approval changes, which constitute the global standard for product life-cycle management are providing clarity and helping national regulatory authorities in establishing guidance while improving time-lines for an efficient regulation of products. Consequently, the regulatory situation for post-approval changes and guideline implementation is changing but there is a disparity between different countries. While the guidelines are gradually being implemented in some countries and also being considered in other countries, the need for regional workshops and further training on post-approval changes was a common theme reiterated by many participants. Given the complexities relating to post-approval changes in different regions/countries, there was a clear understanding among all participants that an efficient approach for product life-cycle management at a national level is needed to ensure faster availability of high standard, safe and efficacious medicines to patients as per the World Health Assembly Resolution 67.21.
Collapse
Affiliation(s)
- Meenu Wadhwa
- National Institute for Biological Standards and Control, Medicines and Healthcare Products Regulatory Agency, Potters Bar, United Kingdom.
| | - Hye-Na Kang
- World Health Organization, Avenue Appia 20, CH-1211, Geneva, Switzerland.
| | - Teeranart Jivapaisarnpong
- National Biopharmaceutical Facility, King Mongkut's University of Technology Thonburi, Bangkhuntian, Bangkok, 10150, Thailand.
| | -
- International MSD International GmbH, Singapore
| | | | | | - Mary Casas Levano
- General Directorate of Medicines Supplies and Drugs (DIGEMID), San Miguel, Peru
| | | | | | | | | | | | | | - Kyung Min Choi
- Ministry of Food and Drug Safety (MFDS), Republic of Korea
| | | | | | | | - Mumun Gencoglu
- International Federation of Pharmaceutical Manufacturers Association, Switzerland
| | | | | | | | | | | | | | | | - Aleksei Iarutkin
- Federal Service for Surveillance in Healthcare (Roszdravnadzor), Russian Federation
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | - Desi Eka Putri
- National Agency of Drug and Food Control (NADFC), Indonesia
| | | | | | - Maria Savkina
- The FSBI "SCEEMP of the Ministry of Health of the Russian Federation, Russian Federation
| | | | | | | | | | | | | | - HyeonHo Song
- ILDONG Pharmaceutical Co., Ltd, Republic of Korea
| | | | | | - Meenu Wadhwa
- National Institute for Biological Standards and Control, United Kingdom
| | | | | | | |
Collapse
|
24
|
Wadhwa M, Rigsby P, Behr-Gross ME. Collaborative study for the establishment of Etanercept Biological Reference Preparation Batch 1. Pharmeur Bio Sci Notes 2020; 2020:203-205. [PMID: 33021469] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/11/2023]
Abstract
Three preparations of the human tumour necrosis factor (TNF) receptor II Fc fusion protein (TNFR II-Fc) Etanercept were formulated and lyophilised at the National Institute for Biological Standards & Control (NIBSC) prior to evaluation in a collaborative study for their suitability to serve as a World Health Organization (WHO) International Standard (IS)/European Pharmacopoeia (Ph. Eur.) Biological Reference Preparation (BRP) for the potency assay of Etanercept. Seven laboratories tested the preparations using an in vitro cell-based bioassay (TNF-α neutralisation) prescribed by the Ph. Eur. monograph on Etanercept (2895). The results of this study indicated that the candidate preparation, coded 13/204, established as the first IS for Etanercept with an assigned potency for TNF neutralisation activity of 10 000 IU per ampoule was also suitable to serve as Ph. Eur. BRP batch 1. The results were compared to those obtained with different cell-based neutralisation assays that were used by further laboratories in the context of establishing the 1st WHO IS for Etanercept. Based on these analyses, preparation 13/204 was adopted by the Ph. Eur. Commission as Etanercept BRP batch 1 with an assigned potency of 10 000 IU per ampoule.
Collapse
Affiliation(s)
- M Wadhwa
- National Institute for Biological Standards and Control (NIBSC), Biotherapeutics Division, Blanche Lane, South Mimms, Potters Bar, EN6 3QG, UK
| | - P Rigsby
- National Institute for Biological Standards and Control (NIBSC), Analytical and Biological Sciences Division, Blanche Lane, South Mimms, Potters Bar, EN6 3QG, UK
| | - M-E Behr-Gross
- European Directorate for the Quality of Medicines & HealthCare, Department of Biological Standardisation, OMCL Network & HealthCare (DBO), Council of Europe, Strasbourg, France
| |
Collapse
|
25
|
Wadhwa M, Rigsby P, Behr-Gross ME. Collaborative study for the establishment of Infliximab Biological Reference Preparation Batch 1. Pharmeur Bio Sci Notes 2020; 2020:49-52. [PMID: 32459170] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/11/2023]
Abstract
Two preparations of the chimeric anti-Tumour Necrosis Factor (TNF) monoclonal antibody Infliximab were formulated and lyophilised at the National Institute for Biological Standards & Control (NIBSC) prior to evaluation in a collaborative study for their suitability to serve as a World Health Organization (WHO) International Standard (IS)/European Pharmacopoeia (Ph. Eur.) Biological Reference Preparation (BRP) for the potency assay of Infliximab. Twenty-six laboratories tested the preparations using different in vitro cell-based bioassays (TNF-α neutralisation, antibody-dependent cellular cytotoxicity and complement-dependent cytotoxicity) and binding assays. Amongst them, 19 laboratories performed cell-based bioassays. The results of this study indicated that the candidate preparation coded 16/170 was suitable to serve as an International Standard for Infliximab based on the data obtained for biological activity. This candidate standard was established in 2017 as the first International Standard for Infliximab with an assigned potency for TNF neutralisation activity of 500 IU per ampoule. In the same study, the suitability of preparation 16/170 of Infliximab to serve as the European Pharmacopoeia (Ph. Eur.) Biological Reference Preparation (BRP) for the Infliximab potency assay as described in the Ph. Eur. monograph on Infliximab concentrated solution (2928) was also evaluated. The corresponding analysis, based on the measurement of the inhibitory action of anti-human TNF (Infliximab) on the cytotoxic activity of TNF-alpha, was performed using data from a subset of 9 laboratories using the TNF-alpha-sensitive fibrosarcoma cell line WEHI-164. The results obtained were compared to those obtained from different cell-based neutralisation assays that were used by other laboratories in the context of establishing the 1st World Health Organization (WHO) International Standard (IS) for Infliximab. Based on the analyses, preparation 16/170 was adopted by the Ph. Eur. Commission in June 2018 as Infliximab BRP batch 1 with an assigned potency of 500 IU per ampoule.
Collapse
Affiliation(s)
- M Wadhwa
- National Institute for Biological Standards and Control (NIBSC), Blanche Lane, South Mimms, Potters Bar, EN6 3QG, UK
| | - P Rigsby
- National Institute for Biological Standards and Control (NIBSC), Blanche Lane, South Mimms, Potters Bar, EN6 3QG, UK
| | - M-E Behr-Gross
- European Directorate for the Quality of Medicines & HealthCare, Council of Europe, Strasbourg, France
| |
Collapse
|
26
|
Lamba J, Wadhwa M, Bakshi M. In Vitro Methane Production Potential and In Sacco Degradability of Non-Leguminous and Leguminous Straws and Stovers. ANIM NUTR FEED TECHN 2020. [DOI: 10.5958/0974-181x.2020.00012.8] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/24/2022]
|
27
|
Hundal J, Wadhwa M, Bakshi M. Effect of Supplementing Herbal Feed Additive Anethum sowa on Nutrient Utilization, Productive Performance and Carcass Characteristics of Male Beetal Kids. ANIM NUTR FEED TECHN 2020. [DOI: 10.5958/0974-181x.2020.00003.7] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/24/2022]
|
28
|
Hundal J, Wadhwa M, Sharma A, Singh G, Kaur H. Evaluation of newly developed maize hybrids for yield, whole plant composition and ensiling characteristics under Indian climate. ANIM NUTR FEED TECHN 2020. [DOI: 10.5958/0974-181x.2020.00035.9] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
|
29
|
Proudfoot AEI, Wadhwa M. WHO International Standards and Reference Preparations for Cytokines and Growth Factors. J Leukoc Biol 2020; 107:159-160. [DOI: 10.1002/jlb.3lt0419-120] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/08/2019] [Accepted: 04/09/2019] [Indexed: 11/09/2022] Open
Affiliation(s)
| | - Meenu Wadhwa
- ICIS Standards CommitteeCytokine & Growth Factors SectionBiotherapeutics GroupNational Institute for Biological Standards and Control (NIBSC)Medicines and Healthcare Products Regulatory Agency Hertfordshire United Kingdom
| |
Collapse
|
30
|
Civoli F, Kasinath A, Cai XY, Wadhwa M, Exley A, Oldfield P, Alvandkouhi S, Schaffar G, Chappell J, Bowsher R, Devanarayan V, Marini J, Rebarchak S, Anderson M, Koppenburg V, Lester T. Recommendations for the Development and Validation of Immunogenicity Assays in Support of Biosimilar Programs. AAPS J 2019; 22:7. [PMID: 31792633 DOI: 10.1208/s12248-019-0386-y] [Citation(s) in RCA: 14] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Received: 07/11/2019] [Accepted: 09/18/2019] [Indexed: 11/30/2022]
Abstract
For biosimilar drug development programs, it is essential to demonstrate that there are no clinically significant differences between the proposed biosimilar therapeutic (biosimilar) and its reference product (originator). Based on a stepwise comprehensive comparability exercise, the biosimilar must demonstrate similarity to the originator in physicochemical characteristics, biological activity, pharmacokinetics, efficacy, and safety, including immunogenicity. The goal of the immunogenicity assessment is to evaluate potential differences between the proposed biosimilar product and the originator product in the incidence and severity of human immune responses. Establishing that there are no clinically meaningful differences in the immune response between the products is a key element in the demonstration of biosimilarity. An issue of practical, regulatory, and financial importance is to establish whether a two-assay (based on the biosimilar and originator respectively) or a one-assay approach (based on the biosimilar) is optimal for the comparative immunogenicity assessment. This paper recommends the use of a single, biosimilar-based assay for assessing immunogenic similarity in support of biosimilar drug development. The development and validation of an ADA assay used for a biosimilar program should include all the assessments recommended for an innovator program (10-16, 29). In addition, specific parameters also need to be evaluated, to gain confidence that the assay can detect antibodies against both the biosimilar and the originator. Specifically, the biosimilar and the originator should be compared in antigenic equivalence, to assess the ability of the biosimilar and the originator to bind in a similar manner to the positive control(s), as well as in the confirmatory assay and drug tolerance experiments. Practical guidance for the development and validation of anti-drug antibody (ADA) assays to assess immunogenicity of a biosimilar in comparison to the originator, using the one-assay approach, are described herein.
Collapse
Affiliation(s)
| | | | - Xiao-Yan Cai
- Accurant Biotech, Inc., Cranbury, New Jersey, USA
| | - Meenu Wadhwa
- Medicines and Healthcare Products Regulatory Agency (MHRA), National Institute for Biological Standards and Control (NIBSC), Hertfordshire, UK
| | - Andrew Exley
- Regulatory Division, Medicines and Healthcare Products Regulatory Agency (MHRA), London, UK
| | | | | | | | | | | | | | - Joseph Marini
- Janssen Research & Development, LLC, Spring House, Pennsylvania, USA
| | - Shannon Rebarchak
- Janssen Research & Development, LLC, Spring House, Pennsylvania, USA
| | | | | | - Todd Lester
- BioAgilytix Labs, Durham, North Carolina, USA
| |
Collapse
|
31
|
Gurjar SA, Wheeler JX, Wadhwa M, Thorpe R, Kimber I, Derrick JP, Dearman RJ, Metcalfe C. The impact of thioredoxin reduction of allosteric disulfide bonds on the therapeutic potential of monoclonal antibodies. J Biol Chem 2019; 294:19616-19634. [PMID: 31727737 PMCID: PMC6926469 DOI: 10.1074/jbc.ra119.010637] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/14/2019] [Revised: 11/04/2019] [Indexed: 12/21/2022] Open
Abstract
Therapeutic mAbs are used to manage a wide range of cancers and autoimmune disorders. However, mAb-based treatments are not always successful, highlighting the need for a better understanding of the factors influencing mAb efficacy. Increased levels of oxidative stress associated with several diseases are counteracted by the activities of various oxidoreductase enzymes, such as thioredoxin (Trx), which also reduces allosteric disulfide bonds in proteins, including mAbs. Here, using an array of in vitro assays, we explored the functional effects of Trx-mediated reduction on the mechanisms of action of six therapeutic mAbs. We found that Trx reduces the interchain disulfide bonds of the mAbs, after which they remain intact but have altered function. In general, this reduction increased antigen-binding capacity, resulting in, for example, enhanced tumor necrosis factor (TNF) neutralization by two anti-TNF mAbs. Conversely, Trx reduction decreased the antiproliferative activity of an anti-tyrosine kinase-type cell-surface receptor HER2 mAb. In all of the mAbs, Fc receptor binding was abrogated by Trx activity, with significant loss in both complement-dependent cytotoxicity and antibody-dependent cellular cytotoxicity (ADCC) activity of the mAbs tested. We also confirmed that without alkylation, Trx-reduced interchain disulfide bonds reoxidize, and ADCC activity is restored. In summary, Trx-mediated reduction has a substantial impact on the functional effects of an mAb, including variable effects on antigen binding and Fc function, with the potential to significantly impact mAb efficacy in vivo.
Collapse
Affiliation(s)
- Shalom A Gurjar
- Division of Biotherapeutics, The National Institute for Biological Standards and Control, Blanche Lane, South Mimms, Potters Bar, Hertfordshire EN6 3QG, United Kingdom
| | - Jun X Wheeler
- Division of Technology Development and Infrastructure, National Institute for Biological Standards and Control, Blanche Lane, South Mimms, Potters Bar, Hertfordshire EN6 3QG, United Kingdom
| | - Meenu Wadhwa
- Division of Biotherapeutics, The National Institute for Biological Standards and Control, Blanche Lane, South Mimms, Potters Bar, Hertfordshire EN6 3QG, United Kingdom
| | - Robin Thorpe
- Division of Biotherapeutics, The National Institute for Biological Standards and Control, Blanche Lane, South Mimms, Potters Bar, Hertfordshire EN6 3QG, United Kingdom
| | - Ian Kimber
- Lydia Becker Institute of Immunology and Inflammation, School of Biological Sciences, Faculty of Biology, Medicine and Health, Manchester Academic Health Science Centre, University of Manchester, Manchester M13 9PT, United Kingdom
| | - Jeremy P Derrick
- Lydia Becker Institute of Immunology and Inflammation, School of Biological Sciences, Faculty of Biology, Medicine and Health, Manchester Academic Health Science Centre, University of Manchester, Manchester M13 9PT, United Kingdom
| | - Rebecca J Dearman
- Lydia Becker Institute of Immunology and Inflammation, School of Biological Sciences, Faculty of Biology, Medicine and Health, Manchester Academic Health Science Centre, University of Manchester, Manchester M13 9PT, United Kingdom
| | - Clive Metcalfe
- Division of Biotherapeutics, The National Institute for Biological Standards and Control, Blanche Lane, South Mimms, Potters Bar, Hertfordshire EN6 3QG, United Kingdom
| |
Collapse
|
32
|
Proudfoot A, Wadhwa M. WHO International Standards and reference preparations for cytokines and growth factors. Cytokine 2019; 123:154797. [PMID: 31401403 DOI: 10.1016/j.cyto.2019.154797] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
Affiliation(s)
- Amanda Proudfoot
- Novimmune SA14, Chemin des Aulx1228 Plan Les Ouates, Geneva, Switzerland
| | - Meenu Wadhwa
- Cytokine & Growth Factors Section, Biotherapeutics Group, National Institute for Biological Standards and Control (NIBSC), Medicines and Healthcare products Regulatory Agency, Hertfordshire, UK.
| |
Collapse
|
33
|
Proudfoot AE, Wadhwa M. WHO International Standards and Reference Preparations for Cytokines and Growth Factors. J Interferon Cytokine Res 2019; 39:438-439. [DOI: 10.1089/jir.2019.0078] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Affiliation(s)
| | - Meenu Wadhwa
- ICIS Standards Committee Member, Cytokine and Growth Factors Section, Biotherapeutics Group, National Institute for Biological Standards and Control (NIBSC), Medicines and Healthcare Products Regulatory Agency (MHRA), Hertfordshire, United Kingdom
| |
Collapse
|
34
|
Hundal J, Singh I, Wadhwa M, Singh C, Uppal C, Kaur G. Effect of Punica granatum and Tecomella undulata supplementation on nutrient utilization, enteric methane emission and growth performance of Murrah male buffaloes. J Anim Feed Sci 2019. [DOI: 10.22358/jafs/109237/2019] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
|
35
|
Deuri P, Sood N, Wadhwa M, Bakshi M. Screening Tree Leaves for Bio-active Compounds and their Effect on In vitro Fermentation and Methane Production from Total Mixed Ration. ANIM NUTR FEED TECHN 2019. [DOI: 10.5958/0974-181x.2019.00022.2] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
|
36
|
Metcalfe C, Dougall T, Bird C, Rigsby P, Behr-Gross ME, Wadhwa M, Study POT. The first World Health Organization International Standard for infliximab products: A step towards maintaining harmonized biological activity. MAbs 2018; 11:13-25. [PMID: 30395763 PMCID: PMC6343779 DOI: 10.1080/19420862.2018.1532766] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/28/2022] Open
Abstract
Due to the increase in the number of infliximab products, the need for global harmonization of the bioactivity of this monoclonal antibody was recognized by the World Health Organization (WHO). In response, the National Institute for Biological Standards and Control (NIBSC) developed the first international standard (IS) for infliximab, which targets tumour necrosis factor (TNF). Each ampoule is assigned values of 500 IU of TNF neutralizing activity and 500 IU of binding activity. Two preparations of infliximab were formulated and lyophilized at NIBSC prior to evaluation in a collaborative study for their suitability to serve as an IS for the in vitro biological activity of infliximab. The study involved participants using in vitro cell-based bioassays (TNF neutralization, antibody-dependent cell-mediated cytotoxicity and complement-dependent cytotoxicity) and binding assays. The results of this study showed that the candidate preparation, coded 16/170, is suitable as an IS for infliximab bioactivity. This infliximab IS from NIBSC, is intended to support in vitro bioassay calibration and validation by defining international units of bioactivity. The proposed unitages, however, are not intended to revise product labelling or dosing requirements, as any decisions regarding this relies solely with the regulatory authorities. Furthermore, the infliximab IS is not intended for determining the specific activity of products, nor to serve any regulatory role in defining biosimilarity. We briefly discuss the future use of WHO international standards in supporting the global harmonisation of biosimilar infliximab products.
Collapse
Affiliation(s)
- Clive Metcalfe
- a Division of Biotherapeutics , National Institute for Biological Standards and Control (NIBSC) , South Mimms , Potters Bar, Hertfordshire , UK
| | - Thomas Dougall
- b Division of Technology Development and Infrastructure , National Institute for Biological Standards and Control , South Mimms , UK
| | - Chris Bird
- a Division of Biotherapeutics , National Institute for Biological Standards and Control (NIBSC) , South Mimms , Potters Bar, Hertfordshire , UK
| | - Peter Rigsby
- b Division of Technology Development and Infrastructure , National Institute for Biological Standards and Control , South Mimms , UK
| | - Marie-Emmanuelle Behr-Gross
- c Department of Biological Standardisation , OMCL Network & HealthCare (DBO), European Directorate for the Quality of Medicines and HealthCare (EDQM) , Strasbourg , France
| | - Meenu Wadhwa
- a Division of Biotherapeutics , National Institute for Biological Standards and Control (NIBSC) , South Mimms , Potters Bar, Hertfordshire , UK
| | | |
Collapse
|
37
|
Jia H, Thelwell C, Dilger P, Bird C, Daniels S, Wadhwa M. Endothelial cell functions impaired by interferon in vitro: Insights into the molecular mechanism of thrombotic microangiopathy associated with interferon therapy. Thromb Res 2018; 163:105-116. [PMID: 29407621 DOI: 10.1016/j.thromres.2018.01.039] [Citation(s) in RCA: 37] [Impact Index Per Article: 6.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/14/2017] [Revised: 12/22/2017] [Accepted: 01/22/2018] [Indexed: 12/23/2022]
Abstract
INTRODUCTION Interferon (IFN)-α and IFN-β approved for treatment of chronic hepatitis C viral infection and multiple sclerosis respectively have been linked to thrombotic microangiopathy (TMA) affecting renal function. Since the molecular mechanisms underlying this severe complication remain largely unclear, we aimed to investigate whether IFN affects directly in vitro endothelial cell functions associated with angiogenesis and blood haemostasis, as well as endothelial cell-derived vasodilators of nitric oxide (NO) and prostacyclin. METHODS Proliferation and survival of human umbilical vein endothelial cells (HUVECs) were measured by BrdU incorporation and alamarBlue assays. Angiogenesis was evaluated in co-cultures of HUVECs and human dermal fibroblasts. Fibrinolysis molecules were measured with ELISA. NO and prostacyclin were measured using a fluorescent NO-specific probe and a competitive enzyme immunoassay, respectively. RESULTS HUVEC proliferation was dose-dependently inhibited by IFN-β1a and IFN-β1b, but not by IFN-α2a and IFN-α2b. Consistently, IFN-β1a and IFN-β1b also reduced survival of HUVECs, but this again was not observed with IFN-α. However, both IFN subtypes inhibited VEGF-induced development of capillary-like structures, but the effect of IFN-α was less potent than IFN-β. In addition, both IFN subtypes upregulated interferon inducible protein 10 production from treated co-cultures while suppressing angiogenesis. Furthermore, intracellular NO generation was reduced by IFN-α2a and IFN-β1a, whereas prostacyclin release from HUVECs was not affected by IFN. Importantly, both IFN-β1a- and IFN-β1b-treated HUVECs showed a marked reduction in urokinase-type plasminogen activator release and a much greater secretion of plasminogen activator inhibitor-1 than tissue-type plasminogen activator compared with untreated cells, suggesting decreased fibrinolytic activity. IFN-α, however was less effective in modulating the fibrinolysis system. CONCLUSIONS We demonstrate the detrimental effects of IFN on endothelial cell functions mediated with angiogenesis and fibrinolysis, which could potentially cause the loss of physiological endothelium thromboresistance and facilitate the development of vascular complications in a clinical setting. Mechanistically, our findings have implications for understanding how IFN therapy can foster the development of TMA.
Collapse
Affiliation(s)
- Haiyan Jia
- Section of Cytokines and Growth Factors, Division of Biotherapeutics, National Institute for Biological Standards and Control, United Kingdom.
| | - Craig Thelwell
- Section of Haemostasis, Division of Biotherapeutics, National Institute for Biological Standards and Control, United Kingdom
| | - Paula Dilger
- Section of Cytokines and Growth Factors, Division of Biotherapeutics, National Institute for Biological Standards and Control, United Kingdom
| | - Chris Bird
- Section of Cytokines and Growth Factors, Division of Biotherapeutics, National Institute for Biological Standards and Control, United Kingdom
| | - Sarah Daniels
- Section of Haemostasis, Division of Biotherapeutics, National Institute for Biological Standards and Control, United Kingdom
| | - Meenu Wadhwa
- Section of Cytokines and Growth Factors, Division of Biotherapeutics, National Institute for Biological Standards and Control, United Kingdom
| |
Collapse
|
38
|
Wadhwa M, Kumar B, Bakshi M. Nutritional Evaluation of Ensiled Baby Corn Fodder as Livestock Feed. ANIM NUTR FEED TECHN 2018. [DOI: 10.5958/0974-181x.2018.00025.2] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
|
39
|
Wadhwa M, Kang HN, Hamel H, Jivapaisarnpong T. WHO informal consultation on development of guidelines on procedures and data requirements for changes to approved biotherapeutic products, Seoul, Republic of Korea, 27-28 April 2017. Biologicals 2018; 52:83-91. [PMID: 29289489 DOI: 10.1016/j.biologicals.2017.12.002] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/06/2017] [Accepted: 12/13/2017] [Indexed: 11/25/2022] Open
Abstract
In April 2017, WHO convened an informal consultation to develop WHO guidelines on procedures and data requirements for changes to approved biotherapeutic products. The objective of the meeting was to review the draft of WHO guidelines and the comments received from the public consultation. The guidelines were recognized by the participants as a tool for regulatory convergence and harmonization. Regulation of changes to approved biotherapeutic products is a key in ensuring that products of consistent quality, safety and efficacy are distributed after they receive authorization or licensure. Participants agreed that the guidelines would contribute to assuring the continued quality, safety and efficacy throughout the life-cycle of biotherapeutics as well as continuity in supply and access. In the meeting, participants further requested WHO should assist national regulatory authorities in improving technical expertise in the evaluation of biotherapeutics and their post-approval changes by organizing implementation workshops and developing case studies and e-training modules on various technical topics. At its meeting in October 2017, the WHO Expert Committee on Biological Standardization formally adopted the WHO guidelines on procedures and data requirements for changes to approved biotherapeutic products.
Collapse
Affiliation(s)
- Meenu Wadhwa
- National Institute for Biological Standards and Control, Blanche Lane, South Mimms, Potters Bar, Herts EN6 3QG, United Kingdom.
| | - Hye-Na Kang
- Essential Medicines and Health Products (EMP) Department, World Health Organization (WHO), Avenue Appia 20, CH-1211, Geneva 27, Switzerland.
| | - Hugo Hamel
- Monoclonal Antibodies Division, Biologics and Genetic Therapies Directorate, Health Canada, 100 Eglantine Driveway, A/L: 0602B, Tunney's Pasture, Ottawa, Ontario, K1A 0K9, Canada.
| | - Teeranart Jivapaisarnpong
- Department of Medical Sciences, Ministry of Public Health, Tivanon Road, Nonthaburi 11000, Thailand.
| | | |
Collapse
|
40
|
Abstract
SummaryHaematopoietic growth factors constitute an important group of proteins that predominantly regulate the process of haematopoiesis. While some of these proteins have a very broad array of action on very early haematopoietic progenitors leading to multi-lineage increases in haematopoietic cell production and differentiation, others act in a restricted manner on specific committed terminally differentiated cell types. On the basis of their unique spectrum of activities, several factors are approved for clinical use in various indications while others are under investigation in the clinic either alone or as combination therapy. In this review, we have described factors which directly and in some cases indirectly influence haematopoiesis with particular focus on those factors which are either approved or show potential for clinical use. A brief description of the products that are currently available for clinical use is also provided. At present, several new products which include fusion proteins, peptide mimetics are either at the pre-clinical stage or in clinical development for various indications and these are also briefly described.
Collapse
|
41
|
Cludts I, Spinelli FR, Morello F, Hockley J, Valesini G, Wadhwa M. Reprint of "Anti-therapeutic antibodies and their clinical impact in patients treated with the TNF antagonist adalimumab". Cytokine 2017; 101:70-77. [PMID: 29174881 DOI: 10.1016/j.cyto.2017.11.007] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/26/2016] [Revised: 02/14/2017] [Accepted: 02/15/2017] [Indexed: 02/05/2023]
Abstract
Patients treated with the TNF antagonist adalimumab develop anti-therapeutic antibodies (ATA), the prevalence of which varies depending on the assay used. Most assays are compromised due to the presence of adalimumab in the clinical samples. Our objective was to develop an antibody assay, applicable for clinical testing, which overcomes the limitation of therapeutic interference and to further determine the relationship between ATA development, adalimumab levels and disease activity in patients with rheumatoid arthritis (RA), psoriatic arthritis (PsA) or ankylosing spondylitis (AS). Use of an electrochemiluminescence platform permitted development of fit-for-purpose immunoassays. Serum samples from patients, taken prior to and at 12 and 24 weeks of treatment, were retrospectively analysed for levels of adalimumab and ATA. Overall, the antibody prevalence was 43.6% at 12 weeks and 41% at 24 weeks of treatment. Disruption of immune complexes by acid dissociation, a strategy often adopted for this purpose, only marginally increased the antibody prevalence to 48.7% and 46% at 12 and 24 weeks respectively. We found that antibody formation was associated with decreasing levels of circulating adalimumab, but no direct effect on disease activity was evident as assessed using DAS28 for RA patients and BASDAI for PsA and AS patients. However, a negative correlation of free adalimumab trough levels with disease activity scores was observed. Data showed that adalimumab levels can serve as an indicator of ATA development which can then be confirmed by ATA testing. Monitoring of both therapeutic and antibodies should be considered during adalimumab therapy to allow clinicians to personalise treatments for maximal therapeutic outcomes.
Collapse
Affiliation(s)
- Isabelle Cludts
- Biotherapeutics Group, Cytokines and Growth Factor Section, National Institute for Biological Standards and Control, Medicines and Healthcare products Regulatory Agency, Blanche Lane, Potters Bar, Hertfordshire EN6 3QG, United Kingdom.
| | - Francesca Romana Spinelli
- Department of Internal Medicine and Medical Specialties, Sapienza University of Rome, Piazzale Aldo Moro 5, 00185 Roma, Italy
| | - Francesca Morello
- Department of Internal Medicine and Medical Specialties, Sapienza University of Rome, Piazzale Aldo Moro 5, 00185 Roma, Italy
| | - Jason Hockley
- Biostatistics, National Institute for Biological Standards and Control, Medicines and Healthcare products Regulatory Agency, Blanche Lane, Potters Bar, Hertfordshire EN6 3QG, United Kingdom
| | - Guido Valesini
- Department of Internal Medicine and Medical Specialties, Sapienza University of Rome, Piazzale Aldo Moro 5, 00185 Roma, Italy
| | - Meenu Wadhwa
- Biotherapeutics Group, Cytokines and Growth Factor Section, National Institute for Biological Standards and Control, Medicines and Healthcare products Regulatory Agency, Blanche Lane, Potters Bar, Hertfordshire EN6 3QG, United Kingdom
| |
Collapse
|
42
|
Cludts I, Spinelli FR, Morello F, Hockley J, Valesini G, Wadhwa M. Anti-therapeutic antibodies and their clinical impact in patients treated with the TNF antagonist adalimumab. Cytokine 2017; 96:16-23. [PMID: 28279855 PMCID: PMC5484178 DOI: 10.1016/j.cyto.2017.02.015] [Citation(s) in RCA: 19] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/26/2016] [Revised: 02/14/2017] [Accepted: 02/15/2017] [Indexed: 11/30/2022]
Abstract
ECL-based assays for measurement of adalimumab and adalimumab antibodies. Performance of ECL antibody assay not significantly improved by acid dissociation. Negative correlation between levels of antibody and free adalimumab. Negative correlation between adalimumab level and disease activity scores.
Patients treated with the TNF antagonist adalimumab develop anti-therapeutic antibodies (ATA), the prevalence of which varies depending on the assay used. Most assays are compromised due to the presence of adalimumab in the clinical samples. Our objective was to develop an antibody assay, applicable for clinical testing, which overcomes the limitation of therapeutic interference and to further determine the relationship between ATA development, adalimumab levels and disease activity in patients with rheumatoid arthritis (RA), psoriatic arthritis (PsA) or ankylosing spondylitis (AS). Use of an electrochemiluminescence platform permitted development of fit-for-purpose immunoassays. Serum samples from patients, taken prior to and at 12 and 24 weeks of treatment, were retrospectively analysed for levels of adalimumab and ATA. Overall, the antibody prevalence was 43.6% at 12 weeks and 41% at 24 weeks of treatment. Disruption of immune complexes by acid dissociation, a strategy often adopted for this purpose, only marginally increased the antibody prevalence to 48.7% and 46% at 12 and 24 weeks respectively. We found that antibody formation was associated with decreasing levels of circulating adalimumab, but no direct effect on disease activity was evident as assessed using DAS28 for RA patients and BASDAI for PsA and AS patients. However, a negative correlation of free adalimumab trough levels with disease activity scores was observed. Data showed that adalimumab levels can serve as an indicator of ATA development which can then be confirmed by ATA testing. Monitoring of both therapeutic and antibodies should be considered during adalimumab therapy to allow clinicians to personalise treatments for maximal therapeutic outcomes.
Collapse
Affiliation(s)
- Isabelle Cludts
- Biotherapeutics Group, Cytokines and Growth Factor Section, National Institute for Biological Standards and Control, Medicines and Healthcare products Regulatory Agency, Blanche Lane, Potters Bar, Hertfordshire EN6 3QG, United Kingdom.
| | - Francesca Romana Spinelli
- Department of Internal Medicine and Medical Specialties, Sapienza University of Rome, Piazzale Aldo Moro 5, 00185 Roma, Italy
| | - Francesca Morello
- Department of Internal Medicine and Medical Specialties, Sapienza University of Rome, Piazzale Aldo Moro 5, 00185 Roma, Italy
| | - Jason Hockley
- Biostatistics, National Institute for Biological Standards and Control, Medicines and Healthcare products Regulatory Agency, Blanche Lane, Potters Bar, Hertfordshire EN6 3QG, United Kingdom
| | - Guido Valesini
- Department of Internal Medicine and Medical Specialties, Sapienza University of Rome, Piazzale Aldo Moro 5, 00185 Roma, Italy
| | - Meenu Wadhwa
- Biotherapeutics Group, Cytokines and Growth Factor Section, National Institute for Biological Standards and Control, Medicines and Healthcare products Regulatory Agency, Blanche Lane, Potters Bar, Hertfordshire EN6 3QG, United Kingdom
| |
Collapse
|
43
|
Ratanji KD, Derrick JP, Kimber I, Thorpe R, Wadhwa M, Dearman RJ. Influence of Escherichia coli chaperone DnaK on protein immunogenicity. Immunology 2017; 150:343-355. [PMID: 27859059 PMCID: PMC5290234 DOI: 10.1111/imm.12689] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/18/2016] [Revised: 10/30/2016] [Accepted: 11/05/2016] [Indexed: 01/11/2023] Open
Abstract
The production of anti-drug antibodies can impact significantly upon the safety and efficacy of biotherapeutics. It is known that various factors, including aggregation and the presence of process-related impurities, can modify and augment the immunogenic potential of proteins. The purpose of the investigations reported here was to characterize in mice the influence of aggregation and host cell protein impurities on the immunogenicity of a humanized single-chain antibody variable fragment (scFv), and mouse albumin. Host cell protein impurities within an scFv preparation purified from Escherichia coli displayed adjuvant-like activity for responses to the scFv in BALB/c strain mice. The 70 000 MW E. coli chaperone protein DnaK was identified as a key contaminant of scFv by mass spectrometric analysis. Preparations of scFv lacking detectable DnaK were spiked with recombinant E. coli DnaK to mimic the process-related impurity. Mice were immunized with monomeric and aggregated preparations, with and without 0·1% DnaK by mass. Aggregation alone enhanced IgM and IgG2a antibody responses, but had no significant effect on total IgG or IgG1 responses. The addition of DnaK further enhanced IgG and IgG2a antibody responses, but only in the presence of aggregated protein. DnaK was shown to be associated with the aggregated scFv by Western blot analysis. Experiments with mouse albumin showed an overall increase in immunogenicity with protein aggregation alone, and the presence of DnaK increased the vigour of the IgG2a antibody response further. Collectively these data reveal that DnaK has the potential to modify and enhance immunogenicity when associated with aggregated protein.
Collapse
Affiliation(s)
- Kirsty D. Ratanji
- Faculty of Biology, Medicine and HealthSchool of Biological SciencesThe University of ManchesterManchesterUK
| | - Jeremy P. Derrick
- Faculty of Biology, Medicine and HealthSchool of Biological SciencesThe University of ManchesterManchesterUK
| | - Ian Kimber
- Faculty of Biology, Medicine and HealthSchool of Biological SciencesThe University of ManchesterManchesterUK
| | - Robin Thorpe
- National Institute for Biological Standards and ControlPotters BarHertfordshireUK
| | - Meenu Wadhwa
- National Institute for Biological Standards and ControlPotters BarHertfordshireUK
| | - Rebecca J. Dearman
- Faculty of Biology, Medicine and HealthSchool of Biological SciencesThe University of ManchesterManchesterUK
| |
Collapse
|
44
|
Chauhan G, Ray K, Sahu S, Roy K, Jain V, Wadhwa M, Panjwani U, Kishore K, Singh S. Adenosine A1 receptor antagonist mitigates deleterious effects of sleep deprivation on adult neurogenesis and spatial reference memory in rats. Neuroscience 2016; 337:107-116. [DOI: 10.1016/j.neuroscience.2016.09.007] [Citation(s) in RCA: 17] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/31/2016] [Revised: 08/30/2016] [Accepted: 09/05/2016] [Indexed: 01/19/2023]
|
45
|
Wadhwa M, Mytych DT, Bird C, Barger T, Dougall T, Han H, Rigsby P, Kromminga A, Thorpe R. Establishment of the first WHO Erythropoietin antibody reference panel: Report of an international collaborative study. J Immunol Methods 2016; 435:32-42. [DOI: 10.1016/j.jim.2016.05.005] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/18/2015] [Revised: 03/25/2016] [Accepted: 05/03/2016] [Indexed: 10/21/2022]
|
46
|
Ratanji KD, Dearman RJ, Kimber I, Thorpe R, Wadhwa M, Derrick JP. Editor's Highlight: Subvisible Aggregates of Immunogenic Proteins Promote a Th1-Type Response. Toxicol Sci 2016; 153:258-70. [PMID: 27370416 PMCID: PMC5036615 DOI: 10.1093/toxsci/kfw121] [Citation(s) in RCA: 25] [Impact Index Per Article: 3.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/29/2022] Open
Abstract
Protein aggregation is associated with enhanced immunogenicity of biotherapeutics. As a result, regulatory guidelines recommend screening for aggregation during bioprocessing. However, the mechanisms underlying the enhanced immunogenicity of aggregates are poorly understood. In the investigations described herein, the immunogenicity in mice of a humanized single chain variable antibody fragment (scFv) purified after expression in Escherichia coli has been examined. Reproducible scFv aggregates were obtained within the subvisible particle size range (mean diameter 2 µm) using thermal and mechanical stresses. Intraperitoneal immunization of BALB/c strain mice with 1 mg/ml of aggregated or monomeric scFv induced similar IgG and IgG1 antibody responses. In contrast, aggregate preparations stimulated significantly higher levels of anti-scFv IgG2a antibody than did the monomer. In comparative studies, aggregates of ovalbumin (OVA) within the subvisible particle size range were prepared by stir stress, and their immunogenicity compared with that of monomeric OVA in mice. Aggregated and monomeric OVA induced similar anti-OVA IgG and IgG1 antibody responses, whereas IgG2a antibody levels were significantly higher in aggregate-immunized mice. Furthermore, cytokine profiles in supernatants taken from splenocyte-dendritic cell co-cultures were consistent with aggregated preparations inducing a T helper (Th) 1-type response. Aggregated proteins within the subvisible range were therefore shown to induce a preferential Th1 type response, whereas monomeric proteins elicited a selective Th2 response. These data indicate that protein aggregation can impact on both the vigor and quality of immune responses.
Collapse
Affiliation(s)
- Kirsty D Ratanji
- *Faculty of Life Sciences, The University of Manchester, C1256, Michael Smith Building, Dover St, Manchester M13 9PT, UK
| | - Rebecca J Dearman
- *Faculty of Life Sciences, The University of Manchester, C1256, Michael Smith Building, Dover St, Manchester M13 9PT, UK
| | - Ian Kimber
- *Faculty of Life Sciences, The University of Manchester, C1256, Michael Smith Building, Dover St, Manchester M13 9PT, UK
| | - Robin Thorpe
- National Institute for Biological Standards and Control, Potters Bar, Hertfordshire EN6 3QG
| | - Meenu Wadhwa
- National Institute for Biological Standards and Control, Potters Bar, Hertfordshire EN6 3QG
| | - Jeremy P Derrick
- *Faculty of Life Sciences, The University of Manchester, C1256, Michael Smith Building, Dover St, Manchester M13 9PT, UK;
| |
Collapse
|
47
|
Wadhwa M, Bachhawat A. A genetic screen for increasing metabolic flux in the isoprenoid pathway of Saccharomyces cerevisiae: Isolation of SPT15 mutants using the screen. Metab Eng Commun 2016; 3:164-172. [PMID: 29468122 PMCID: PMC5779727 DOI: 10.1016/j.meteno.2016.05.004] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/02/2016] [Revised: 05/24/2016] [Accepted: 05/25/2016] [Indexed: 01/17/2023] Open
Abstract
A genetic screen to identify mutants that can increase flux in the isoprenoid pathway of yeast has been lacking. We describe a carotenoid-based visual screen built with the core carotenogenic enzymes from the red yeast Rhodosporidium toruloides. Enzymes from this yeast displayed the required, higher capacity in the carotenoid pathway. The development also included the identification of the metabolic bottlenecks, primarily phytoene dehydrogenase, that was subjected to a directed evolution strategy to yield more active mutants. To further limit phytoene pools, a less efficient version of GGPP synthase was employed. The screen was validated with a known flux increasing gene, tHMG1. New mutants in the TATA binding protein SPT15 were isolated using this screen that increased the yield of carotenoids, and an alternate isoprenoid, α-Farnesene confirming increase in overall flux. The findings indicate the presence of previously unknown links to the isoprenoid pathway that can be uncovered using this screen.
Collapse
|
48
|
Jia H, Dilger P, Bird C, Wadhwa M. IL-27 Promotes Proliferation of Human Leukemic Cell Lines Through the MAPK/ERK Signaling Pathway and Suppresses Sensitivity to Chemotherapeutic Drugs. J Interferon Cytokine Res 2016; 36:302-16. [PMID: 27119567 PMCID: PMC4854210 DOI: 10.1089/jir.2015.0091] [Citation(s) in RCA: 20] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/28/2023] Open
Abstract
IL-27 is a pleiotropic cytokine of the IL-6/IL-12 family with diverse biological functions. Previous in vivo studies have suggested the antitumor activities of IL-27 in animal models, whereas clinical observations indicate the link of IL-27 in tumor progression. IL-27 has recently been shown to cause inhibition of proliferation on primary leukemic cells from pediatric patients, but information on its role in human leukemic cell lines is limited. In the present study, we investigated the ability of IL-27 to regulate cell growth and survival of various human leukemic cell lines. Our results showed that in human leukemic cell lines coexpressing both IL-27R chains, IL-27Rα and gp130, IL-27 did not inhibit cell growth, but caused dose-dependent proliferation of the acute myeloid leukemic cell line, OCI-AML5, and the erythroleukemic cell lines, TF-1, UT-7, and UT-7/EPO. Consistent with this, IL-27 promoted cell survival and reduced TNF-α-induced apoptosis of the leukemic cell lines. IL-27 also decreased the responsiveness of the leukemic cells to chemotherapeutic drugs, cytarabine and daunorubicin. We observed that IL-27 induced the activation of STAT1/3 and ERK1/2 in the leukemic cells. Growth stimulation by IL-27 was suppressed by the specific MEK inhibitor, U0126, indicating that IL-27-induced cell proliferation is mainly mediated through the activation of the MAPK/ERK signaling pathway. The present study is the first demonstration of the proliferative and antichemotherapeutic properties of IL-27 in human leukemic cell lines, suggesting that IL-27 can play an unfavorable role in tumor growth and can be an important determinant in the chemoresponsiveness of certain subtypes of human leukemia.
Collapse
Affiliation(s)
- Haiyan Jia
- Cytokines and Growth Factors Section, Biotherapeutics Group, National Institute for Biological Standards and Control , Potters Bar, United Kingdom
| | - Paula Dilger
- Cytokines and Growth Factors Section, Biotherapeutics Group, National Institute for Biological Standards and Control , Potters Bar, United Kingdom
| | - Chris Bird
- Cytokines and Growth Factors Section, Biotherapeutics Group, National Institute for Biological Standards and Control , Potters Bar, United Kingdom
| | - Meenu Wadhwa
- Cytokines and Growth Factors Section, Biotherapeutics Group, National Institute for Biological Standards and Control , Potters Bar, United Kingdom
| |
Collapse
|
49
|
|
50
|
|